Sora Lee1, Eric J Rellinger1, Kwang Woon Kim1, Brian T Craig1, Carmelle V Romain1, Jingbo Qiao1, Dai H Chung2. 1. Department of Pediatric Surgery, Vanderbilt University Medical Center, Nashville, TN. 2. Department of Pediatric Surgery, Vanderbilt University Medical Center, Nashville, TN; Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, TN. Electronic address: dai.chung@vanderbilt.edu.
Abstract
BACKGROUND: MYCN amplification is a key molecular hallmark of high-risk neuroblastoma. Previously considered an "undruggable" target, MYCN transcription can be disrupted by inhibiting the bromodomain and the extraterminal (BET) domain family of proteins that regulates MYCN transcription epigenetically. JQ1 is a potent, small-molecule BET inhibitor that induces cell-cycle arrest and initiates apoptosis in neuroblastoma. Here, we sought to validate the antitumorigenic effects of JQ1 in neuroblastoma and to evaluate whether blocking N-myc expression with JQ1 promotes neural differentiation. METHODS: We determined the effects in vitro of JQ1 treatment on human neuroblastoma cell growth in both monolayer and sphere-forming conditions. Subcutaneous neuroblastoma xenografts were used for an in vivo study. Western blotting and immunohistochemistry were performed to evaluate the effects on neural differentiation and stem cell markers. RESULTS: JQ1 treatment blocked neuroblastoma cell growth in both monolayer and sphere-forming conditions; JQ1 also attenuated the growth of neuroblastoma xenograft in athymic nude mice. Neurofilament expression was enhanced with JQ1 treatment, indicating that JQ1 induces neuronal differentiation. Sphere forming conditions resulted in increased expression of multiple stem cell markers; these effects were reversed with JQ1 treatment. CONCLUSION: BET inhibition attenuates progression and promotes neural differentiation of neuroblastoma in vitro and in vivo in mice, providing insight into potential clinical applications of BET inhibitors in the treatment of patients with neuroblastoma.
BACKGROUND:MYCN amplification is a key molecular hallmark of high-risk neuroblastoma. Previously considered an "undruggable" target, MYCN transcription can be disrupted by inhibiting the bromodomain and the extraterminal (BET) domain family of proteins that regulates MYCN transcription epigenetically. JQ1 is a potent, small-molecule BET inhibitor that induces cell-cycle arrest and initiates apoptosis in neuroblastoma. Here, we sought to validate the antitumorigenic effects of JQ1 in neuroblastoma and to evaluate whether blocking N-myc expression with JQ1 promotes neural differentiation. METHODS: We determined the effects in vitro of JQ1 treatment on humanneuroblastoma cell growth in both monolayer and sphere-forming conditions. Subcutaneous neuroblastoma xenografts were used for an in vivo study. Western blotting and immunohistochemistry were performed to evaluate the effects on neural differentiation and stem cell markers. RESULTS: JQ1 treatment blocked neuroblastoma cell growth in both monolayer and sphere-forming conditions; JQ1 also attenuated the growth of neuroblastoma xenograft in athymic nude mice. Neurofilament expression was enhanced with JQ1 treatment, indicating that JQ1 induces neuronal differentiation. Sphere forming conditions resulted in increased expression of multiple stem cell markers; these effects were reversed with JQ1 treatment. CONCLUSION:BET inhibition attenuates progression and promotes neural differentiation of neuroblastoma in vitro and in vivo in mice, providing insight into potential clinical applications of BET inhibitors in the treatment of patients with neuroblastoma.
Authors: Jennifer A Mertz; Andrew R Conery; Barbara M Bryant; Peter Sandy; Srividya Balasubramanian; Deanna A Mele; Louise Bergeron; Robert J Sims Journal: Proc Natl Acad Sci U S A Date: 2011-09-26 Impact factor: 11.205
Authors: Jake E Delmore; Ghayas C Issa; Madeleine E Lemieux; Peter B Rahl; Junwei Shi; Hannah M Jacobs; Efstathios Kastritis; Timothy Gilpatrick; Ronald M Paranal; Jun Qi; Marta Chesi; Anna C Schinzel; Michael R McKeown; Timothy P Heffernan; Christopher R Vakoc; P Leif Bergsagel; Irene M Ghobrial; Paul G Richardson; Richard A Young; William C Hahn; Kenneth C Anderson; Andrew L Kung; James E Bradner; Constantine S Mitsiades Journal: Cell Date: 2011-09-01 Impact factor: 41.582
Authors: H Takenobu; O Shimozato; T Nakamura; H Ochiai; Y Yamaguchi; M Ohira; A Nakagawara; T Kamijo Journal: Oncogene Date: 2010-09-06 Impact factor: 9.867
Authors: Ulrica K Westermark; Margareta Wilhelm; Anna Frenzel; Marie Arsenian Henriksson Journal: Semin Cancer Biol Date: 2011-08-09 Impact factor: 15.707
Authors: Christopher J Ott; Nadja Kopp; Liat Bird; Ronald M Paranal; Jun Qi; Teresa Bowman; Scott J Rodig; Andrew L Kung; James E Bradner; David M Weinstock Journal: Blood Date: 2012-08-17 Impact factor: 22.113
Authors: Sidong Huang; Jamila Laoukili; Mirjam T Epping; Jan Koster; Michael Hölzel; Bart A Westerman; Wouter Nijkamp; Akiko Hata; Shahab Asgharzadeh; Robert C Seeger; Rogier Versteeg; Roderick L Beijersbergen; René Bernards Journal: Cancer Cell Date: 2009-04-07 Impact factor: 31.743
Authors: Anne-Marie Schlitter; Carmen Dorneburg; Thomas F E Barth; Joachim Wahl; Johannes H Schulte; Silke Brüderlein; Klaus-Michael Debatin; Christian Beltinger Journal: PLoS One Date: 2012-08-10 Impact factor: 3.240
Authors: Trevor J Pugh; Olena Morozova; Edward F Attiyeh; Shahab Asgharzadeh; Jun S Wei; Daniel Auclair; Scott L Carter; Kristian Cibulskis; Megan Hanna; Adam Kiezun; Jaegil Kim; Michael S Lawrence; Lee Lichenstein; Aaron McKenna; Chandra Sekhar Pedamallu; Alex H Ramos; Erica Shefler; Andrey Sivachenko; Carrie Sougnez; Chip Stewart; Adrian Ally; Inanc Birol; Readman Chiu; Richard D Corbett; Martin Hirst; Shaun D Jackman; Baljit Kamoh; Alireza Hadj Khodabakshi; Martin Krzywinski; Allan Lo; Richard A Moore; Karen L Mungall; Jenny Qian; Angela Tam; Nina Thiessen; Yongjun Zhao; Kristina A Cole; Maura Diamond; Sharon J Diskin; Yael P Mosse; Andrew C Wood; Lingyun Ji; Richard Sposto; Thomas Badgett; Wendy B London; Yvonne Moyer; Julie M Gastier-Foster; Malcolm A Smith; Jaime M Guidry Auvil; Daniela S Gerhard; Michael D Hogarty; Steven J M Jones; Eric S Lander; Stacey B Gabriel; Gad Getz; Robert C Seeger; Javed Khan; Marco A Marra; Matthew Meyerson; John M Maris Journal: Nat Genet Date: 2013-01-20 Impact factor: 38.330
Authors: Andrew D Woods; Noah E Berlow; Michael V Ortiz; Filemon Dela Cruz; Armaan Siddiquee; Diego F Coutinho; Reshma Purohit; Katherine E Tranbarger Freier; Joel E Michalek; Melvin Lathara; Kevin Matlock; Ganapati Srivivasa; Brigitte Royer-Pokora; Renata Veselska; Andrew L Kung; Charles Keller Journal: Pediatr Blood Cancer Date: 2021-10-24 Impact factor: 3.838
Authors: Eric J Rellinger; Chandrasekhar Padmanabhan; Jingbo Qiao; Brian T Craig; Hanbing An; Jing Zhu; Hernán Correa; Alex G Waterson; Craig W Lindsley; R Daniel Beauchamp; Dai H Chung Journal: Oncotarget Date: 2017-07-20
Authors: Luz Jubierre; Carlos Jiménez; Eric Rovira; Aroa Soriano; Constantino Sábado; Luis Gros; Anna Llort; Raquel Hladun; Josep Roma; Josep Sánchez de Toledo; Soledad Gallego; Miguel F Segura Journal: Exp Mol Med Date: 2018-04-27 Impact factor: 8.718
Authors: Atif Zafar; Wei Wang; Gang Liu; Xinjie Wang; Wa Xian; Frank McKeon; Jennifer Foster; Jia Zhou; Ruiwen Zhang Journal: Med Res Rev Date: 2020-11-06 Impact factor: 12.944
Authors: James A Saltsman; William J Hammond; Nicole J C Narayan; David Requena; Helmuth Gehart; Gadi Lalazar; Michael P LaQuaglia; Hans Clevers; Sanford Simon Journal: Cancers (Basel) Date: 2020-09-18 Impact factor: 6.639